Harvest Fund Management Co. Ltd Increases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Harvest Fund Management Co. Ltd increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 42.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,307 shares of the medical device company's stock after purchasing an additional 7,848 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in DexCom were worth $2,013,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA boosted its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Larson Financial Group LLC grew its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth $38,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of DexCom during the 4th quarter valued at $49,000. Institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 105,009 shares of company stock worth $8,044,178. Corporate insiders own 0.30% of the company's stock.

Remove Ads

DexCom Trading Up 2.1 %

NASDAQ DXCM traded up $1.52 on Monday, reaching $75.32. The stock had a trading volume of 2,688,740 shares, compared to its average volume of 3,917,473. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a fifty day moving average price of $83.33 and a two-hundred day moving average price of $77.03. The firm has a market capitalization of $29.43 billion, a price-to-earnings ratio of 52.67, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent analyst reports. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.